NSE: DRREDDY | BSE: 500124

Turnaround Potential

Download real time

1275.80 0.60 (0.05%)

25.08% Gain from 52W Low

2.6M NSE+BSE Volume

NSE 03 Dec, 2025 10:47 AM (IST)

106,481

Market Cap

High in industry

Beta 1Year

Very Low volatility

HC Ruling

Delhi HC reportedly allows Dr Reddy's to manufacture and export its weight-loss drug, Semaglutide See details

Dr. Reddy's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DRREDDY, BSE:500124 Dr. Reddy's Laboratories Ltd.

Search Inside the pdf :

Dr. Reddy's Laboratories Ltd.

29 Oct 2025

1275.80

0.05%

A muted quarter as robust growth across non-US markets was offset by US pricing pressure.

Sell: Dr. Reddy's Laboratories Ltd.

Target

Deven Choksey

Although the company continues to strengthen its presence through new launches, portfolio expansion, and biosimilar development, persistent pricing pressure in the U.S. generics business and adverse product mix are expected to remain key headwinds to its overall profitability.

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr. Reddy's Laboratories Ltd.

27 Oct 2025

1275.80

0.05%

Result Update:Dr Reddys Labs

Hold: Dr. Reddy's Laboratories Ltd.

Target

Axis Direct

We maintain our HOLD recommendation on the stock.

Number of FII/FPI investors decreased from 917 to 872 in Sep 2025 qtr

Dr. Reddy's Laboratories Ltd.

27 Oct 2025

1275.80

0.05%

Dr Reddy's Laboratories

Buy: Dr. Reddy's Laboratories Ltd.

Target

ICICI Direct

About the stock: Dr Reddy's (DRL) business encompasses generic formulations sales across US, Europe, RoW markets and branded generics in India and Russia CIS. The business also comprises of API sales under the head PSAI. The company...

Number of FII/FPI investors decreased from 917 to 872 in Sep 2025 qtr

Dr. Reddy's Laboratories Ltd.

26 Oct 2025

1275.80

0.05%

GM weakness persists; pipeline uncertainty heightens

Sell: Dr. Reddy's Laboratories Ltd.

Target

Emkay

The 2QFY26 margin performance of Dr Reddy’s was marginally weaker than our expectations (in line with street estimates; adjusted for one-offs), with the gross margin (GM) decline being sharper than our expectations (at 55%, GM logged at its lowest since the launch of gRevlimid) and largely a consequence of lower-than-expected gRevlimid sales.

Dr. Reddy's Laborato.. has an average target of 1281.89 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

26 Oct 2025

1275.80

0.05%

Launches critical to revive growth

Hold: Dr. Reddy's Laboratories Ltd.

Target

ICICI Securities Limited

Dr. Reddy’s Laboratories’ (DRL) Q2FY26 revenue was slightly ahead of our expectations, though EBITDA and profit were in line. Revenue growth of 9.8% YoY was boosted by consolidation (65-70%) of the acquired NRT portfolio (~8% of sales) and acquisition of other branded products.

Dr. Reddy's Laborato.. has an average target of 1281.89 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

26 Oct 2025

1275.80

0.05%

Dr. Reddy's Laboratories (DRRD IN) Q2FY26 Result Update ...

Sell: Dr. Reddy's Laboratories Ltd.

Prabhudas Lilladhar

Number of FII/FPI investors decreased from 917 to 872 in Sep 2025 qtr

Dr. Reddy's Laboratories Ltd.

25 Oct 2025

1275.80

0.05%

Earnings steady despite US pressure

Neutral: Dr. Reddy's Laboratories Ltd.

Target

Motilal Oswal

Dr Reddy’s Labs (DRRD) delivered slightly better-than-expected revenue/EBITDA (3%/5% beat) in 2QFY26. Higher other income and a lower tax rate led to a 14% beat in PAT.

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr. Reddy's Laboratories Ltd.

11 Sep 2025

1275.80

0.05%

Stock Flash

Sell: Dr. Reddy's Laboratories Ltd.

Deven Choksey

Dr. Reddy’s Laboratories Ltd. has entered into a definitive agreement with Janssen Pharmaceutica NV, an affiliate of Johnson & Johnson, to acquire the STUGERON® brand along with its leading local brands STUGERON® FORTE and STUGERON® PLUS.

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr. Reddy's Laboratories Ltd.

29 Jul 2025

1275.80

0.05%

Price Erosion across the US portfolio to remain the key overhang for its overall business

Sell: Dr. Reddy's Laboratories Ltd.

Deven Choksey

Revenue: For Q1FY26, the revenue increased by 11.4% YoY (+0.5% QoQ) to INR 85,721 Mn, below our estimates by 3.0%, led by weakness in North America, which was partially offset by higher momentum across Europe and the Emerging markets.

Number of FII/FPI investors decreased from 917 to 872 in Sep 2025 qtr

Dr. Reddy's Laboratories Ltd.

24 Jul 2025

1275.80

0.05%

Dr. Reddy's Laboratories (DRRD IN) Q1FY26 Result Update ...

Sell: Dr. Reddy's Laboratories Ltd.

Target

Prabhudas Lilladhar

Dr. Reddy's (DRRD) Q1FY26 EBITDA adjusted for licensing income was in line with our estimate. The base business margins and US sales ex of gRevlimid continued to remain weak. We have scale up base business margins from the current level of 15-16% to +21-22% in FY27E. Our FY26 and FY27E EPS broadly remain unchanged. DRRD have been investing cash flow from gRevlimid to build pipeline across peptides, biosimilars and GLP products; benefits of that may take some time. Further thin US pipeline in near term and competition in...

Number of FII/FPI investors decreased from 917 to 872 in Sep 2025 qtr

Is Dr. Reddy's Laboratories Ltd. worth buying?

538 Votes:

Buy 77.88%

Sell 12.64%

Hold 9.48%

RESEARCH REPORTS

Sell SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf